TN-Clinical and Translational Science Institute, University of Tennessee, Health Science Center, Memphis, Tennessee, USA; and the Department of Epidemiology, College of Public Health, and the Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA.
Nutr Rev. 2019 Dec 1;77(12):890-902. doi: 10.1093/nutrit/nuz037.
Vitamin D deficiency is highly prevalent across the world. The existing evidence suggests vitamin D may have beneficial effects on serum lipid profiles and thus cardiovascular health.
The objective of this systematic review and meta-analysis was to examine the effect of vitamin D supplementation on serum lipid profiles.
Original randomized controlled trials (RCTs) examining the effect of vitamin D supplementation on serum lipid profiles and published before July 2018 were identified by searching online databases, including PubMed, Google Scholar, and ScienceDirect, using a combination of relevant keywords.
Data on study characteristics, effect size, measure of variation, type of vitamin D supplementation, and duration of follow-up were extracted by the author.
PRISMA guidelines for systematic reviews were followed. Random effects (DerSimonian and Laird [D-V)] models were used to pool standardized mean differences in total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides between the active and the placebo arms of RCT studies. Between-study heterogeneities were assessed using Cochrane Q and I2, and publication bias was assessed using Begg's test, Egger's test, and funnel plot.
A total of 41 RCTs comprising 3434 participants (n = 1699 in the vitamin D supplementation arm and n = 1735 in the placebo arm) were identified and included in the meta-analysis. Approximately 63.4% of study participants were women, with 14 studies conducted entirely among women. Approximately 24% of the trials had follow-up duration >6 months, whereas the remaining 76% had follow-up duration of <6 months. The standardized mean differences (SMDs) and 95% confidence intervals (CIs) for comparing the change from baseline to follow-up between the vitamin D supplementation arm and the placebo (control) arm were as follows: total cholesterol = -0.17 (-0.28 to -0.06); LDL cholesterol = -0.12 (-0.23 to -0.01); triglycerides = -0.12 (-0.25 to 0.01); and HDL cholesterol = -0.19 (-0.44 to 0.06). After removing a trial that was an outlier based on the magnitude of the effect size, the SMD for triglycerides was -0.15 (-0.24 to -0.06) and that for HDL cholesterol was -0.10 (-0.28 to 0.09). The improvements in total cholesterol and triglycerides were more pronounced in participants with baseline vitamin D deficiency.
Vitamin D supplementation appeared to have a beneficial effect on reducing serum total cholesterol, LDL cholesterol, and triglyceride levels but not HDL cholesterol levels. Vitamin D supplementation may be useful in hypercholesterolemia patients with vitamin D insufficiency who are at high risk of cardiovascular diseases.
维生素 D 缺乏在全球范围内普遍存在。现有证据表明,维生素 D 可能对血清脂质谱产生有益影响,从而对心血管健康有益。
本系统评价和荟萃分析的目的是研究维生素 D 补充对血清脂质谱的影响。
通过在线数据库(包括 PubMed、Google Scholar 和 ScienceDirect)搜索,使用相关关键词组合,确定了截至 2018 年 7 月之前发表的关于维生素 D 补充对血清脂质谱影响的原始随机对照试验(RCT)。
作者提取了研究特征、效应量、变异度量、维生素 D 补充类型和随访时间的数据。
按照系统评价 PRISMA 指南进行。使用随机效应(DerSimonian 和 Laird [D-V])模型对 RCT 研究中活性药物组和安慰剂组之间的总胆固醇、低密度脂蛋白(LDL)胆固醇、高密度脂蛋白(HDL)胆固醇和甘油三酯的标准化均数差值进行汇总。使用 Cochrane Q 和 I2 评估研究间异质性,并使用 Begg 检验、Egger 检验和漏斗图评估发表偏倚。
共确定并纳入了 41 项 RCT,包括 3434 名参与者(维生素 D 补充组 1699 名,安慰剂组 1735 名)。大约 63.4%的研究参与者为女性,其中 14 项研究完全在女性中进行。大约 24%的试验随访时间>6 个月,而其余 76%的试验随访时间<6 个月。与安慰剂(对照)组相比,维生素 D 补充组从基线到随访的变化的标准化均数差值(SMD)和 95%置信区间(CI)如下:总胆固醇=-0.17(-0.28 至-0.06);低密度脂蛋白胆固醇=-0.12(-0.23 至-0.01);甘油三酯=-0.12(-0.25 至 0.01);高密度脂蛋白胆固醇=-0.19(-0.44 至 0.06)。根据效应量的大小排除一个异常值试验后,甘油三酯的 SMD 为-0.15(-0.24 至-0.06),高密度脂蛋白胆固醇的 SMD 为-0.10(-0.28 至 0.09)。在基线维生素 D 缺乏的参与者中,总胆固醇和甘油三酯的改善更为明显。
维生素 D 补充似乎对降低血清总胆固醇、低密度脂蛋白胆固醇和甘油三酯水平有有益作用,但对高密度脂蛋白胆固醇水平没有作用。维生素 D 补充可能对患有维生素 D 不足且患心血管疾病风险高的高胆固醇血症患者有用。